The British National Health Service (NHS) has approved two new breast cancer drugs that will “change the lives” of patients.

The FDA has previously rejected the drugs because of the high cost. According to reports, up to 8,300 people with breast cancer each year will receive either polycoclib or ribociclib, after the regulator has confirmed that drugs will be routinely available.

These drugs slow the development of breast cancer for at least 10 months, so patients can postpone chemotherapy to the advanced stages of the disease to avoid its devastating side effects.

The National Institutes of Health (NHS) has praised the effectiveness of the drugs, which has been one of the most important developments in the treatment of cancer for decades. It works to inhibit the proteins of CDK4 and CDK6. The patient will need only one pill a day.

Negotiations have been held on the high prices of these drugs, and the Commission has reached a discount of about 2,950 pounds per month of the cost of medicine.

“We hope this is a step towards more effective treatment for patients with breast cancer, an advanced stage of cancer,” said Baroness Delith Morgan, CEO of Breast Cancer Now. Now thousands of women have extra time to treat the disease before reaching advanced stages and save their lives.”